Tumor-Specific Photothermal-Therapy-Assisted Immunomodulation via Multiresponsive Adjuvant Nanoparticles

© 2023 Wiley-VCH GmbH.

Bibliographische Detailangaben
Veröffentlicht in:Advanced materials (Deerfield Beach, Fla.). - 1998. - 35(2023), 18 vom: 12. Mai, Seite e2300086
1. Verfasser: Liu, Tao (VerfasserIn)
Weitere Verfasser: Zhu, Man, Chang, Xiaowei, Tang, Xiaoyu, Yuan, Pingyun, Tian, Ran, Zhu, Zeren, Zhang, Yanmin, Chen, Xin
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2023
Zugriff auf das übergeordnete Werk:Advanced materials (Deerfield Beach, Fla.)
Schlagworte:Journal Article metastasis inhibition multi-responsive adjuvant nanoparticles photothermal-assisted immune cells modulation primary tumor extermination tumor-specific photothermal therapy Adjuvants, Immunologic Gold 7440-57-5 Mannose mehr... PHA4727WTP TLR7 protein, human
LEADER 01000caa a22002652c 4500
001 NLM352917237
003 DE-627
005 20250304102456.0
007 cr uuu---uuuuu
008 231226s2023 xx |||||o 00| ||eng c
024 7 |a 10.1002/adma.202300086  |2 doi 
028 5 2 |a pubmed25n1176.xml 
035 |a (DE-627)NLM352917237 
035 |a (NLM)36782382 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Liu, Tao  |e verfasserin  |4 aut 
245 1 0 |a Tumor-Specific Photothermal-Therapy-Assisted Immunomodulation via Multiresponsive Adjuvant Nanoparticles 
264 1 |c 2023 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 12.05.2023 
500 |a Date Revised 12.05.2023 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a © 2023 Wiley-VCH GmbH. 
520 |a Multiresponsive adjuvant nanoparticles (RMmAGL) are fabricated to perform tumor-specific photothermal therapy while regulating the behavior of tumor-associated immune cells for primary tumor eradication and metastasis inhibition. Core-satellite-like RMmAGL have a core of mannose-functionalized mesoporous silica nanoparticles loaded with the TLR7 agonist imiquimod (R837MSN-mannose) connected via hydrazone bonds to satellites of glutamine (Glu)- and lysine (Lys)-comodified gold nanoparticles (AuNPs-Glu/Lys). During therapy, the acidic environment in tumor tissue cleaves the hydrazone bonds to release AuNPs-Glu/Lys, which further accumulate in tumor cells. After internalization, photothermal agents (aggregated AuNPs-Glu/Lys) are generated in situ through the intratumoral enzyme-catalyzed reaction between Glu and Lys, resulting in tumor-specific photothermal therapy. The detachment of AuNPs-Glu/Lys also triggers the release of R837, which matured dendritic cells (DCs) via a vaccine-like mechanism along with the tumor-associated antigens generated by photothermal therapy. These matured DCs further activates surrounding T cells for immunotherapy. Moreover, the resulting free MSN-mannose serves as an artificial glycocalyx to continuously induce the polarization of tumor-associated macrophages from an immunosuppressive phenotype to an inflammatory phenotype, thus further enhancing immunotherapy. Both in vivo and in vitro experiments demonstrate significant inhibition of malignant tumors after therapy 
650 4 |a Journal Article 
650 4 |a metastasis inhibition 
650 4 |a multi-responsive adjuvant nanoparticles 
650 4 |a photothermal-assisted immune cells modulation 
650 4 |a primary tumor extermination 
650 4 |a tumor-specific photothermal therapy 
650 7 |a Adjuvants, Immunologic  |2 NLM 
650 7 |a Gold  |2 NLM 
650 7 |a 7440-57-5  |2 NLM 
650 7 |a Mannose  |2 NLM 
650 7 |a PHA4727WTP  |2 NLM 
650 7 |a TLR7 protein, human  |2 NLM 
700 1 |a Zhu, Man  |e verfasserin  |4 aut 
700 1 |a Chang, Xiaowei  |e verfasserin  |4 aut 
700 1 |a Tang, Xiaoyu  |e verfasserin  |4 aut 
700 1 |a Yuan, Pingyun  |e verfasserin  |4 aut 
700 1 |a Tian, Ran  |e verfasserin  |4 aut 
700 1 |a Zhu, Zeren  |e verfasserin  |4 aut 
700 1 |a Zhang, Yanmin  |e verfasserin  |4 aut 
700 1 |a Chen, Xin  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Advanced materials (Deerfield Beach, Fla.)  |d 1998  |g 35(2023), 18 vom: 12. Mai, Seite e2300086  |w (DE-627)NLM098206397  |x 1521-4095  |7 nnas 
773 1 8 |g volume:35  |g year:2023  |g number:18  |g day:12  |g month:05  |g pages:e2300086 
856 4 0 |u http://dx.doi.org/10.1002/adma.202300086  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 35  |j 2023  |e 18  |b 12  |c 05  |h e2300086